CJC-1295 and Ipamorelin Dosing: How Combined Protocols Are Scheduled

CJC-1295 and ipamorelin dosing depends first on a question many protocols skip: which CJC-1295? The name covers two different molecules with very different half-lives, and that single fact changes how the combination is scheduled. Neither CJC-1295 nor ipamorelin is an FDA-approved drug, so there is no labeled dose; amounts are set by the prescriber for the specific compounded preparation. What is consistent is how protocols are structured — and that is what this guide covers.

Why the pairing is used is covered in why CJC-1295 + ipamorelin is popular; what outcomes the evidence supports is in CJC-1295 / ipamorelin body composition data; and the peptides themselves are on our CJC-1295 + ipamorelin page.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

First: Which CJC-1295?

Where the combination is discussed clinically, it usually means the no-DAC form, because it produces a pulse that mimics natural secretion. Note the regulatory difference between the two components: ipamorelin is listed in Category 1 on our FDA peptide status tracker, while CJC-1295 is not on the tracker and has no established 503A eligibility — confirm with the compounding partner before prescribing. The DAC form is more convenient but produces a continuous "bleed" of GH that is less physiological. Prescriptions and pharmacy labels should state which form is being used; if they do not, clarify before dosing. More on the no-DAC peptide is on our MOD GRF 1-29 page.

How Combined Protocols Are Structured

Route

Subcutaneous injection is the reference route. Oral spray, sublingual, and nasal versions exist with lower bioavailability, so nominal doses are not interchangeable; see which delivery method is best.

Single-Vial or Separate Peptides

The no-DAC combination is often compounded as a single vial containing both peptides in a fixed ratio, so one injection delivers both. Separate vials allow the two to be adjusted independently. Either way, the concentration after reconstitution determines the injected volume — the peptide reconstitution calculator converts vial strength and diluent volume into syringe units.

Timing

• Bedtime dosing is most common, to reinforce the nocturnal GH pulse.
• Fasted or well after a meal. Carbohydrate, insulin, and circulating fatty acids blunt the GH response. Protocols commonly allow a gap of a couple of hours after eating.
• Some protocols add a second daily dose, such as on waking or before training, again away from food.

Frequency

• No-DAC combination: daily or near-daily, because both peptides are short-acting.
• DAC form: far less frequent injection, reflecting its multi-day half-life, with ipamorelin (if used) on its own daily schedule.
• Some clinicians schedule days off each week. The rationale is to maintain pituitary responsiveness; comparative evidence between schedules is limited.

Titration

Protocols typically start conservatively and are adjusted against:

• IGF-1, measured after several weeks and compared with the age- and sex-adjusted reference range
• Tolerability — flushing, water retention, joint aches, hand tingling
• Clinical response, judged over months

The target is a physiological IGF-1 for the patient's age, not the maximum achievable level.

Cycle Length

Protocols are commonly run in blocks of several months with reassessment, and some include planned breaks. Body-composition changes develop gradually, so judging a protocol in its first few weeks is premature.

When the Response Is Inadequate

If IGF-1 barely moves after several weeks on a consistent protocol, prescribers typically work through a short list before changing the peptides:

1. Adherence and technique. Missed doses, incorrect reconstitution, and injecting too close to meals are the most common explanations.
2. Timing relative to food. Moving the dose further from the last meal often improves the response.
3. Route. Non-injection formulations deliver less; switching to subcutaneous injection may be the adjustment.
4. Sleep and metabolic factors. Poor sleep, obesity, and insulin resistance blunt GH secretion regardless of the peptide.
5. Pituitary capacity. A persistently poor response to combined GHRH and ghrelin-receptor stimulation may indicate limited pituitary reserve, which warrants evaluation rather than escalation.

An Example Schedule Structure

The structure below illustrates how a no-DAC protocol is commonly organized. It deliberately omits amounts, which belong to the prescriber and the specific formulation.

Monitoring

GH-related effects — fluid retention, joint aches, numbness or tingling in the hands, rising glucose — are signals to recheck IGF-1 and reassess, not symptoms to push through.

Common Dosing Mistakes

• Not knowing whether the CJC-1295 is DAC or no-DAC.
• Dosing right after eating, which blunts the response.
• Reconstitution errors that change the actual dose delivered. See how to reconstitute peptides.
• Treating oral or nasal doses as equivalent to injections.
• Titrating by feel rather than IGF-1.

Regulatory Status

Ipamorelin is listed in Category 1 (under evaluation) on our FDA peptide status tracker. Compounding status for any specific CJC-1295 form should be confirmed with the compounding partner and against the tracker before building a protocol. Both peptides are prohibited at all times under the WADA Prohibited List.

For how the combination compares with other growth hormone peptides such as sermorelin and tesamorelin, see our hub on peptides for muscle growth. Newtropin connects licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the standard CJC-1295 and ipamorelin dosing?

There is no FDA-labeled dose for either peptide. Amounts are set by the prescriber for the specific compounded preparation and adjusted based on IGF-1 and tolerability.

How often is CJC-1295 with ipamorelin injected?

The common no-DAC combination is injected daily or near-daily. CJC-1295 with DAC lasts several days and is injected far less often.

Should CJC-1295 and ipamorelin be taken at night?

Bedtime dosing on an empty stomach is the most common approach, to reinforce the natural nocturnal GH pulse.

Can I eat after taking CJC-1295 and ipamorelin?

Protocols usually recommend waiting before eating, and dosing a couple of hours after the last meal, because food blunts the growth hormone response.

How long should a CJC-1295 and ipamorelin cycle last?

Protocols commonly run for several months with reassessment, and some include planned breaks. Response is judged over months, not weeks.

What is the difference between CJC-1295 with and without DAC?

The DAC form binds albumin and lasts several days, producing sustained GH elevation. The no-DAC form (MOD GRF 1-29) is short-acting (commonly cited as about 30 minutes) and produces a pulse, which is why it is usually paired with ipamorelin.